RxDoctor Payments Data

Scarlett Virden, APRN

Family · Bartlesville, OKNPI 1205343605

Payments from drug & device makers

$902in general payments, 2019–2025

Across 38 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$166
  • Biotronik Inc.$135
  • AstraZeneca$117
  • Novo Nordisk$87
  • Lilly USA, LLC$84
  • Otsuka America Pharmaceutical, Inc.$79
  • plus $234 from 12 others

What the payments were for

  • Food & beverage$902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$902 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$38,657
Medicare patients
205
Services billed
785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$97,726
FarxigaDapagliflozin Propanediol39$35,861
JardianceEmpagliflozin51$34,270
MounjaroTirzepatide32$34,012
TrulicityDulaglutide25$23,822
RexultiBrexpiprazole13$18,820
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$17,044
EliquisApixaban12$8,092
XareltoRivaroxaban14$7,843
JanumetSitagliptin Phos/Metformin Hcl13$7,243
Atorvastatin Calcium158$2,132
Albuterol Sulfate HfaAlbuterol Sulfate60$1,587
Famotidine47$1,372
Rosuvastatin Calcium80$1,340
Omeprazole71$1,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$87$97,72691 claims
Lilly USA, LLCMounjaro, Trulicity$84$57,83457 claims
AstraZenecaFarxiga, Breztri Aerosphere$117$52,90568 claims
Boehringer IngelheimJardiance$15$34,27051 claims
Otsuka America Pharmaceutical, Inc.Rexulti$79$18,82013 claims
PfizerEliquis$19$8,09212 claims
MerckJanumet$14$7,24313 claims
AbbVieSynthroid$166$78014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,026 family providers in Oklahoma.

Other family in Bartlesville

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →